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Background: Extracorporeal membrane oxygenation (ECMO) treatment alleviates
systemic cardiorespiratory failure. However, it is unclear whether ECMO also improves
microcirculatory function, as the microcirculation can be disturbed despite normal
systemic hemodynamics. We therefore aimed to study the sublingual microcirculation
(SMC) throughout neonatal and pediatric ECMO treatment. We hypothesized that the
SMC improves after starting ECMO, that the SMC differs between venovenous (VV) and
venoarterial (VA) ECMO, and that insufficient recovery of microcirculatory disturbances
during ECMO predicts mortality.
Methods: This single-center prospective longitudinal observational study included 34
consecutive children (April 2016—September 2018). The SMCwas assessed daily with a
handheld vital microscope (integrated with incident dark field illumination) before, during,
and after ECMO. Validated parameters of vessel density, perfusion, and flow quality
were assessed for all vessels (diameter<100µm) and small vessels (<20µm). Linear
mixed models and logistic regression models were built to assess changes over time and
identify significant covariates. Using ROC curves, the predictive values of microcirculatory
parameters were assessed for mortality on ECMO and overall mortality.
Results: The study population comprised 34 patients (median age 0.27 years, 16
neonates, 16 females). Twelve patients were treated with VV and 22 with VA ECMO.
Twelve patients died during ECMO (stopped due to futility) and 3 died after ECMO
but before discharge. Microcirculatory parameters did not change significantly before,
during or after ECMO. Except between microcirculatory flow index (MFI) and mean
arterial pressure (MAP), no significant associations were found between microcirculatory
parameters and global systemic hemodynamics. The probability of an undisturbed MFI
(>2.6) increased with higher MAP (OR: 1.050, 95%CI: 1.008–1.094). Microcirculatory
parameters did not significantly differ between VV and VA ECMO or between survivors
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and non-survivors. None of the microcirculatory parameters could predict mortality on
ECMO or overall mortality.
Conclusion: In this heterogeneous study population, we were not able to demonstrate
an effect of ECMO on the sublingual microcirculation. Microcirculatory parameters did
not change throughout ECMO treatment and did not differ between VV and VA ECMO
or between survivors and non-survivors. Future research should focus on determining
which neonatal and pediatric ECMO patients would benefit from microcirculatory
monitoring and how.
Keywords: microcirculation, hemodynamic monitoring, extracorporeal membrane oxygenation, critical care,
pediatrics, neonates
INTRODUCTION
Extracorporeal membrane oxygenation (ECMO) is an advanced
form of mechanical life support for children with acute
cardiorespiratory failure. While ECMO treatment supports
systemic cardiorespiratory function, it is unclear whether it
improves microcirculatory function and to what extent.
With the introduction of handheld vital microscopy, it has
become possible to visualize the microcirculation in a non-
invasive manner. This has offered insight into microcirculatory
function, i.e., oxygen transport on a microcirculatory level.
In several clinical settings, handheld vital microscopy has
revealed the presence of microcirculatory disturbances despite
normal systemic hemodynamics, thus possibly detecting
otherwise unnoticed disturbed tissue oxygenation (1).
These microcirculatory disturbances have been found to be
independently associated with increased mortality risk (2–4).
The microcirculation of the sublingual mucosa has shown
to be a good representation of other microvascular beds under
a variety of pathophysiologic conditions (5–7). The sublingual
microcirculation has shown to be predictive for survival in adult
patients treated with venoarterial (VA) ECMO for cardiogenic
shock and has even been proposed as a novel marker for
successful weaning from VA ECMO after cardiogenic shock in
adults (8, 9). Top et al. investigated the buccal microcirculation in
neonates with severe respiratory failure treated with VA ECMO
and showed that the buccal microcirculation was preserved after
start of ECMO treatment (10). However, it remains unclear
how the buccal microcirculation relates to other microvascular
beds including the sublingual microcirculation. Whether ECMO
treatment affects the sublingual microcirculation has not yet been
investigated in the neonatal and pediatric population.
The aim of our study is to assess the effect of ECMO
treatment on the sublingual microcirculation in a neonatal and
Abbreviations: ECMO, extracorporeal membrane oxygenation; ECPR,
extracorporeal cardiopulmonary resuscitation; HI, heterogeneity index; IS,
inotrope score; FiO2, fraction inspired O2; MAP, mean arterial pressure;
MFI, microcirculatory flow index; PaCO2, partial CO2 pressure; PaO2,
partial O2 pressure; PELOD-2 score, pediatric logistic organ dysfunction 2
score; PPV, proportion perfused vessels; PVD, perfused vessel density; SMC,
sublingual microcirculation; TVD, total vessel density; VA ECMO, venoarterial
extracorporeal membrane oxygenation; VIS, vasoactive-inotrope score; VV
ECMO, venovenous extracorporeal membrane oxygenation.
pediatric population. We hypothesize that (1) the sublingual
microcirculation improves after start of ECMO treatment, (2)
that microcirculatory parameters differ between venovenous
(VV) and VA ECMO, and (3) that insufficient recovery
of microcirculatory disturbances during ECMO treatment
predicts mortality.
METHODS
Study Design, Population, and Setting
We performed a prospective longitudinal observational study at
the ICU of a tertiary university children’s hospital, which serves
as the national ECMO center, between April 2016 and September
2018. Consecutive ECMO patients were included to acquire a
representative sample of the ECMO population of our institute.
The study was approved by the local medical ethical review board
(Medical Research Ethics Committee Erasmus Medical Center
Rotterdam). Informed consent was waived as standard therapy
was monitored through non-invasive techniques in accordance
with hospital guidelines. Patients aged <18 years treated with
ECMO irrespective of ECMO modus (VV or VA ECMO) and
primary diagnosis were included in the study. Patients needed to
be fully cooperative or sufficiently sedated in order to perform
microcirculatory measurements. If a patient did not meet this
criterion either before or immediately after start of ECMO
treatment, he or she was excluded. The primary study parameters
were the microcirculatory parameters, as described below.
Data Collection
The sublingual microcirculation was assessed with the Cytocam
(Braedius Medical, Huizen, the Netherlands). The Cytocam is
a handheld vital microscopy incorporated with incident dark
field illumination, high magnification lenses and a computer-
controlled high-resolution image sensor (11). International
expert consensus guidelines were followed for both image
acquisition and analysis (12, 13). The handheld probe was
gently positioned on the sublingual mucosa and five clips,
each with a duration of 6 s, were recorded at the following
time points: before start of ECMO treatment, within 24 h after
start ECMO treatment, daily during ECMO treatment, and
finally after ECMO treatment was terminated up to 2 h after
decannulation. Image quality was assessed using the quality
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score developed by Massey et al. (14). If quality criteria were
not met, images were excluded from analysis. Image analysis
was performed oﬄine using semi-automated software AVA 3.2
(MicroVision Medical, Amsterdam, the Netherlands) by an
experienced researcher (ÖE), who was blinded to the origin
of the clips. Image analysis yielded the following functional
parameters for all microcirculatory vessels (diameter <100µm)
and for all small vessels, mainly capillaries, (diameter <20µm):
total vessel density (TVDall/TVD<20µm, mm/mm
2), proportion
perfused vessels (PPVall/PPV<20µm, %), perfused vessel density
(PVDall/PVD<20µm, mm/mm
2), microcirculatory flow index
(MFIall/MFI<20µm, score between 0 and 3) and heterogeneity
index of flow (HI, score between 0 and 1) (12). TVD quantifies
the total vessel area visible in the frame, while PPV gives the
number of perfused vessels per total number of visible vessels
in the frame. PVD describes the functional vessel area visible
in the frame, calculated through the multiplication of TVD and
PPV. MFI is a semi-qualitative score to describe the quality of
flow. To obtain MFI, the screen is divided into four quadrants
and each quadrant is assigned a score between 0 and 3, where
0 = no flow, 1 = intermittent flow, 2 = sluggish flow and 3 =
continuous flow. The average of the scores of the four quadrants
is the MFI. To account for variability between measured areas,
HI can be calculated through the equation [(highest value—lowest
value)/mean value].
Baseline and ECMO characteristics, routine clinical and
hemodynamic parameters and laboratory values were collected
from electronic records and the PEdiatric Logistic Organ
Dysfunction 2 (PELOD-2) score, the inotrope score (IS), and
the vasoactive-inotrope score (VIS) were calculated (15, 16).
Also, mortality on ECMO, ICU length of stay, and survival were
assessed at the end of the study period.
ECMO Treatment
Initiating ECMO support, modus and ECMO settings were
according to a well-established hospital-based ECMO protocol
that did not change over time. Depending on the age of
patients, cannulation in neonates was always by surgical neck
dissection and adapted Seldinger technique. For pediatric
patients, femoral surgical approaches with or without a neck
cannula were used. The ECMO circuit comprised the Medos
DP3 centrifugal pump and either the Medos HILITE LT or the
iLA Activve Membrane Ventilator oxygenators. During ECMO
treatment patients received continuous unfractionated heparin
as anticoagulation with dose adjustments following hospital
treatment guidelines.
Statistical Analysis
Continuous data are presented as median (1st quartile−3rd
quartile) and categorical data as frequency (percentage). To
compare continuous variables between survivors and non-
survivors, between VV and VA ECMO, and between types
of primary diagnoses, the Mann-Whitney U-test and the
Kruskal-Wallis test were used. To account for the fact that
microcirculatory measurements could not always be performed
on a daily basis, measurements were divided over the following
time points for analysis: before start of ECMO, after start
ECMO/ECMO day 1, ECMO day 2/3, ECMO day 4/5, ECMO
day 6/7 and after stop ECMO treatment. If the patient was
indeed measured on a daily basis from day 2 onwards, the first
measurement in the 48 h was used for analysis.
For univariable analyses of repeated measures, linear mixed
models were built for microcirculatory parameters and global
hemodynamic parameters with time point as the single
independent variable, to assess whether these parameters
differed between time points. In addition, linear mixed
models were built for microcirculatory parameters with time
point and another independent variable to explore which
baseline and ECMO demographics and global hemodynamic
parameters (parameters mentioned in Tables 1–3) affected
microcirculatory parameters.
For multivariable analyses of repeated measures, linear mixed
models (continuous outcome parameter: PVD) and logistic
regression models based on generalized estimating equations
with a binomial error distribution and logit link function
(categorical outcome parameter: MFI>2.6) were built. MFI≤2.6
has been proposed and shown, but not yet validated in children,
as the threshold to identify a disturbed microcirculation (3, 4).
Significant independent variables from the univariable analyses
were tested in these multivariable analyses. The independent
variables tested for PVDall and PVD<20µm: pediatric patient,
sex, sildenafil treatment, plasma transfusion in the last 24 h,
crystalloids transfusion in the last 24 h, partial O2 pressure (PaO2,
kPa), and norepinephrine (µg/kg/min); for MFIall:, pediatric
patient: sex, PaO2 (kPa), norepinephrine (µg/kg/min), duration
ECMO treatment (hours), mean arterial pressure (MAP, mmHg),
hemoglobin (L/L), and fraction inspired O2 (FiO2, %) of the
sweep gas flow; for MFI<20µm: pediatric patient, norepinephrine
(µg/kg/min), FiO2 (%), MAP (mmHg), hemoglobin (L/L), and
FiO2 of the sweep gas flow (%). The stepwise backward method
with a p-value selection threshold of 0.2 was then applied to
obtain the final multivariable model. Time point was forced into
both univariable and multivariable models, irrespective of the
p-value. A random intercept was included in the linear mixed
models to account for the within-subject correlations. The linear
mixed models account for missing data in the outcome and no
form of data imputation was used.
Receiver-operating-characteristic (ROC) curves were built to
assess the predictive value of microcirculatory parameters per
time point for mortality on ECMO and overall mortality. Two-
sided p-values lower than 0.05 were considered statistically
significant, but a Bonferroni-adjusted significance level of 0.008
was used for the ROC analyses. Statistical analysis was performed
in IBM SPSS statistics 24 (IBM, Armonk, NY, USA).
RESULTS
Demographics
Figure 1 shows the flow chart for inclusion. Thirty-seven
consecutive patients were included in the study. Three patients
were excluded from analysis as the collected images did not
meet quality criteria. Table 1 describes the general demographics
of the study population. The study population comprised 34
patients, with a median age of 0.27 years, 16 neonates (47%), 16
females (47%), and a median PELOD-2 score of 12 (mortality
risk of >30%). Table 2 describes ECMO-specific demographics.
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TABLE 1 | General demographics study population.
Total Survivors Non-survivors p-value
Patients 34 19 (56%) 15 (44%)
Female 16 (47%) 8 (42%) 8 (53%) 0.515
Age (years) 0.27 (0.01–2.23) 0.02 (0.00–1.47) 0.50 (0.04–2.67) 0.089
Neonate 16 (47%) 12 (63%) 4 (27%) 0.034*
Weight (kg) 5.0 (3.3–13.3) 3.5 (3.3–9.4) 9.0 (3.5–14.0) 0.190
PELOD-2 score on day start ECMO 12 (9–17) 10 (8–13) 13 (11–17) 0.228
Continuous data are presented as median (Q1-Q3), categorical data as n (%). PELOD-2 score, PEdiatric Logistic Organ Dysfunction 2 score. *p-value < 0.05 is considered
statistically significant.
TABLE 2 | ECMO specific demographics study population.
Total (n = 34) Survivors (n = 19) Non-survivors (n = 15) p-value
Type ECMO: 0.350
VV 12 (35%) 8 (42%) 4 (27%)
VA 22 (65%) 11 (58%) 11 (73%)
Type primary diagnosis: 0.374
Respiratory 15 (44,1%) 10 (53%) 5 (33%)
Cardiac 13 (38,2%) 7 (37%) 6 (40%)
ECPR 6 (17,6%) 2 (10%) 4 (27%)
Primary indication for ECMO:
Respiratory insufficiency 3 (8.8%) 2 1
PPHN/PHT 5 (14.7%) 3 2
MAS/PHT 3 (8.8%) 3 0
CDH/PHT 3 (8.8%) 2 1
Near drowning 3 (8.8%) 1 2
Septic shock 1 (2.9%) 0 1
Cardiac failure 4 (11.8%) 3 1
Cardiomyopathy 4 (11.8%) 1 3
Myocarditis 1 (2.9%) 1 0
Cardiogenic shock 1 (2.9%) 1 0
ECPR 6 (17.6%) 2 4
Duration ECMO treatment (hrs) 142.6 (82.4–308.5) 116.5 (81.5–231.5) 242.0 (89.0–366.5) 0.215
Continuous data are presented as median (Q1-Q3), categorical data as n (%). CDH, congenital diaphragmatic hernia; ECMO, extracorporeal membrane oxygenation; ECPR,
extracorporeal cardiopulmonary resuscitation; MAS, meconium aspiration syndrome; PHT, pulmonary hypertension; PPHN, persisting pulmonary hypertension in the newborn; VA,
venoarterial; VV, venovenous. p-value < 0.05 is considered significant.
Twelve patients (35%) received VV ECMO treatment and 22
patients (65%) VA ECMO treatment. Primary indications for
ECMO treatment included 15 respiratory diagnoses (44%), 13
cardiac diagnoses (38%), and 6 extracorporeal cardiopulmonary
resuscitation (ECPR) cases (18%). Four of the 13 cardiac
diagnoses (12%) were cyanotic heart diseases. The median
duration of ECMO treatment was 142.6 h. Type of ECMO,
primary indications for ECMO treatment, and duration of
ECMO treatment did not significantly differ between survivors
and non-survivors.
Univariable Analyses of Microcirculatory
and Global Hemodynamic Parameters
Table 3 shows the microcirculatory and global hemodynamic
parameters per time point. Microcirculatory measurements
were possible in 38% of the study population before start of
ECMO treatment, in 85% after start of ECMO treatment, in
77% on day 2 or 3, in 41% on day 4 or 5 and on day
6 or 7 and in 50% after successful weaning from ECMO.
Microcirculatory parameters did not change after start of and
during ECMO treatment, while global hemodynamic parameters
did show improvement over time. Heart rate, partial CO2
pressure (PaCO2), serum lactate, IS and VIS decreased over
time, while arterial O2 saturation increased. Microcirculatory
parameters did not significantly differ between VV and VA
ECMO or between types of primary diagnosis. In addition,
microcirculatory parameters were not different for patients with
cyanotic heart disease. The 62% of ECMO patients who could
not be measured before the start of ECMO treatment did not
have different microcirculatory parameters at the consecutive
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TABLE 3 | Observed data per time point.
Parameter Before start ECMO
(n = 13)
After start ECMO/on day 1
(n = 29)
ECMO day 2 or 3
(n = 24)
ECMO day 4 or 5
(n = 9)
ECMO day 6 or 7
(n = 7)
After stop ECMO
(n = 11)
p-value
TVDall (mm/mm
2 ) 24.59 (20.71–26.41) 25.48 (23.15 - 28.35) 24.47 (23.13- 26.75) 28.15 (26.80 - 30.09) 27.95 (23.36 - 31.80) 25.35 (23.61 - 26.75) 0.374
PPVall (%) 98.78 (96.49 - 99.16) 99.12 (97.43–99.78) 98.82 (97.27–100) 99.27 (98.01–99.75) 99.74 (98.88–99.90) 99.23 (97.76–100) 0.569
PVDall (mm/mm
2 ) 24.03 (20.14–26.14) 25.38 (23.10–27.99) 24.38 (22.92–25.82) 28.07 (25.90–29.92) 27.43 (23.31–31.71) 25.26 (23.11–26.30) 0.371
MFIall 2.78 (2.48–2.87) 2.87 (2.76- 3) 2.83 (2.73–3) 2.85 (2.64–3) 2.92 (2.64–3) 2.89 (2.73–2.98) 0.880
HIMFI 0.09 (0.09–0.17) 0.07 (0–0.13) 0.09 (0–0.11) 0.13 (0–0.13) 0.04 (0–0.10) 0.05 (0.02–0.15) 0.728
TVD
<20µm (mm/mm
2 ) 21.70 (18.80–23.59) 22.75 (20.68–24.68) 21.47 (20.41–23.90) 26.41 (24.30–26.90) 25.83 (20.63–28.99) 21.91 (20.51–24.23) 0.378
PPV
<20µm (%) 98.62 (96.17–99.40) 99.08 (97.35–99.74) 98.70 (96.93–100) 99.14 (97.87–99.70) 99.71 (98.73–99.89) 99.13 (97.35–100) 0.579
PVD
<20µm (mm/mm
2 ) 21.22 (18.45–23.35) 22.18 (20.40–24.35) 21.16 (19.67–23.40) 24.48 (24.23–26.73) 25.31 (20.58–28.91) 21.65 (19.52–24.04) 0.388
MFI
<20µm 2.38 (2.06–2.71) 2.75 (2.50–3) 2.67 (2.50–3) 2.67 (2.33–3) 2.75 (2.33–3) 2.75 (2.44–3) 0.381
MAP (mmHg) 55 (42–70) 57 (48–66) 58 (51–71) 48 (46–59) 55 (43–58) 47 (38–52) 0.053
HR (bpm) 157 (136–166) 147 (121–156) 134 (106–150) 119 (114–123) 131 (127–147) 145 (122–154) 0.003*
CVP (mmHg) 9 (6–10) 11 (5–17) 10 (6–18) (–) (–) (–) 0.587
Fluid balance (ml/kg/d) 42 (8–75) 40 (26–69) −11 (-40–65) 12 (−26–116) −18 (−21–61) 9 (−4–44) 0.193
pH 7.26 (7.18–7.34) 7.34 (7.23–7.38) 7.36 (7.33–7.42) 7.33 (7.32–7.42) 7.41 (7.29–7.47) 7.29 (7.22–7.44) 0.205
PaO2 (kPa) 11.3 (7.0–18.5) 10.8 (8.0–17.2) 8.7 (6.8–11.3) 10.3 (8.9–11.6) 11.1 (6.9–18.3) 16.7 (11.3–20.9) 0.167
PaCO2 (kPa) 6.4 (5.2–9.1) 5.7 (5.0–6.3) 5.8 (5.5–6.1) 5.6 (5.3–6.6) 5.5 (5.3–7.1) 6.1 (5.2–8.0) 0.017*
SaO2 (%) 90 (83–99) 96 (93–100) 95 (89–98) 97 (93–98) 98 (96–100) 99 (98–100) 0.008*
Hemoglobin (mmol/L) 7.6 (5.9–8.8) 6.7 (6.0–7.7) 7.5 (6.9–7.9) 6.7 (6.5–7.3) 6.5 (6.3–6.9) 6.5 (6.4–6.8) 0.085
Hematocrit (L/L) 0.35 (0.25–0.39) 0.33 (0.29–0.36) 0.34 (0.32–0.36) 0.32 (0.30–0.32) 0.33 (0.30–0.34) 0.32 (0.29–0.35) 0.838
Lactate (mmol/L) 4.1 (1.4–6.0) 3.6 (1.9–8.5) 1.4 (1.2–3.2) 1.3 (1.0–4.9) 1.5 (0.8–3.5) 0.8 (0.6–1.3) <0.001*
IS 12 (0–48) 10 (0–38) 10 (0–24) 0 (0–5) 0 (0–0) 0 (0–4) 0.017*
VIS 72 (0–98) 27 (5- 80) 10 (0–36) 0 (0–5) 2 (0–49) 5 (2–14) 0.002*
On ECMO 0 (0%) 34 (100%) 31 (91%) 22 (64%) 17 (50%) 0 (0%) NA
Mortality 0 (0%) 0 (0%) 2 (6%) 4 (12%) 5 (15%) 12 (35%) NA
Table shows the observed raw data per time point. The last column shows the p-values based on the univariable linear mixed models. Continuous data are presented as median (Q1-Q3), categorical data as n (%). CVP, central venous
pressure; ECMO, extracorporeal membrane oxygenation; HI, heterogeneity index of flow; HR, heart rate; IS, inotrope score; MAP, mean arterial pressure; MFI, microcirculatory flow index; NA, not applicable; PaCO2, partial arterial carbon
dioxide pressure; PaO2, partial arterial oxygen pressure; PPV, proportion perfused vessels; PVD, perfused vessel density; SaO2, arterial oxygen saturation; TVD, total vessel density; VIS, vasoactive inotrope score; * significant change
over time points (univariable linear mixed models, p<0.05).
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FIGURE 1 | Flowchart inclusion study population.
time points than the 38% of ECMO patients who were
measured before ECMO was initiated (p > 0.05). No differences
could be found between the two groups in PELOD-2 score,
type of ECMO, primary indication for ECMO, and mortality
rates (p > 0.05).
Multivariable Analyses of Microcirculatory
Parameters PVD and MFI
Table 4 summarizes the results of the linear mixed models for
PVD. Both PVDall and PVD<20µm were lower if the patient was
a pediatric patient (> 28 days old) or female or had received
plasma transfusion in the last 24 h before measurement. Both
PVDall and PVD<20µm were lower if continuous intravenous
infusion of norepinephrine was administered at a higher dose
or if PaO2 increased. PVD was higher if the patient received
sildenafil or crystalloids in the last 24 h before measurement.
Table 5 summarizes the results of the logistic regression models
for MFI > 2.6. The probability of MFIall > 2.6 was lower in
pediatric patients than in neonates. The probability of MFIall >
2.6 was higher when patients were on ECMO for a longer period,
MAP was higher, or FiO2 of the sweep gas flow was set higher.
The probability of MFIall > 2.6 was lower when PaO2 was higher.
The probability of MFI<20µm > 2.6 was higher with higher MAP
or FiO2 but decreased with higher hemoglobin levels.
Outcome
Twelve patients (35%) died during ECMO treatment, as ECMO
treatment was stopped due to futility, and 3 patients (9%) died
after ECMO treatment before ICU discharge. Leading causes of
death during ECMO treatment were multi-organ failure (n =
5), severe brain damage and multi-organ failure (n = 4), severe
brain damage (n= 2), and no treatment options (n= 1). Leading
causes of death after ECMO treatment were no therapeutic
options (n = 1), severe brain damage (n = 1) and untreatable
pulmonary hypertension (n= 1). The median ICU length of stay
was 15 days (11–23). Before start of ECMO treatment, there were
no significant differences between survivors and non-survivors
in global systemic hemodynamics or need for vasoactive drugs.
Microcirculatory parameters did not differ between survivors
and non-survivors on all time points separately. None of the
microcirculatory parameters measured before start of ECMO
treatment, after start of ECMO treatment or on day 2 or
3 of ECMO treatment could predict mortality on ECMO or
overall mortality as none of the parameters had a significant
area under the curve in the ROC curve analysis, summarized
in Table S1.
DISCUSSION
In our study with consecutively included patients, an effect of
ECMO treatment on the sublingual microcirculation could not
be demonstrated. Microcirculatory parameters did not change
immediately after starting ECMO, nor during or after ECMO
treatment. Microcirculatory parameters did not significantly
differ betweenVV andVAECMO.Multivariable analyses showed
that PVD values were influenced by patients’ age, sex, plasma
transfusion, infusion of norepinephrine, PaO2 levels, sildenafil
treatment, and resuscitation with crystalloids. The probability
of having an MFI > 2.6 was influenced by patients’ age, MAP,
FiO2 settings, PaO2 levels, and hemoglobin levels. Additionally,
microcirculatory parameters did not significantly differ between
survivors and non-survivors and did not predict mortality on
ECMO or overall mortality.
In contrast to our hypothesis, the microcirculation did
not change after the initiation of ECMO treatment in
our study population, despite the effects of ECMO on
systemic hemodynamics. ECMO treatment was started in
patients with cardiovascular and/or respiratory failure when
conventional treatment fell short in the support of global
systemic hemodynamics. After ECMO initiation global systemic
hemodynamics improved and the need for vasoactive and
inotropic drugs and fluid resuscitation decreased. However,
microcirculatory parameters appeared largely unaffected both
before and immediately after initiation of ECMO treatment.
As shown, PPV and MFI values were high before initiation
of ECMO treatment and remained high at consecutive time
points. Statistical analysis did not reveal specified patient groups
in which the microcirculation was compromised before the
initiation of ECMO treatment or changed after initiation of
ECMO treatment. In contrast to adult studies in which the
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TABLE 4 | Multivariable linear mixed models for PVDall and PVD<20µm.
Repeated measures mixed model: PVDall Estimate B 95% CI p-value
Intercept 28.321 24.214–32.429 <0.001
Time point 0.188
Before start ECMO 1.737 −1.242–4.715 0.247
After start ECMO/on day 1 2.856 0.441–5.270 0.021
ECMO day 2 or 3 1.012 −1.550–3.574 0.431
ECMO day 4 or 5 1.455 −1.529–4.439 0.332
ECMO day 6 or 7 2.232 −1.025–5.488 0.174
After stop ECMO 0 (reference) – –
Pediatric patient (>28 days old) (c) −2.294 −4.381–0.207 0.032
Male (c) 1.490 −0.486–3.466 0.134
PaO2 (kPa) −0.118 −0.223–0.012 0.029
No sildenafil treatment (c) −2.165 −4.724–0.394 0.095
No plasma transfusion in last 24 h (c) 1.339 −0.412–3.091 0.131
No crystalloids administration in last 24 h (c) −2.400 −4.342–0.458 0.016
Dose continuous IV norepinephrine (µg/kg/min) −3.996 −7.417–0.580 0.023
Repeated measures mixed model: PVD
<20µm Estimate B 95% CI p-value
Intercept 26.017 22.097–29.936 <0.001
Time point 0.077
Before start ECMO 2.657 −0.210–5.524 0.069
After start ECMO/on day 1 3.627 1.300–5.955 0.003
ECMO day 2 or 3 2.043 −0.427–4.513 0.103
ECMO day 4 or 5 1.840 −1.034–4.714 0.205
ECMO day 6 or 7 2.518 −0.623–5.659 0.113
After stop ECMO 0 (reference) – –
Pediatric patient (>28 days old) (c) −3.192 −5.159–1.225 0.002
Male (c) 1.260 −0.597–3.116 0.176
PaO2 (kPA) −0.132 −0.233–0.030 0.012
No sildenafil treatment (c) −2.783 −5.201–0.365 0.025
No plasma transfusion in last 24 hours (c) 1.716 0.032–3.399 0.046
No crystalloids administration in last 24 hours (c) −2.727 −4.590–0.865 0.005
Dose continuous IV norepinephrine (µg/kg/min) −3.667 −6.931–0.404 0.028
C, categorical variable; CI, confidence interval; ECMO, extracorporeal membrane oxygenation; PaO2, partial O2 pressure; PVD, perfused vessel density.
microcirculation improved in patients with cardiogenic shock
treated with VA ECMO, type of ECMO and type of primary
diagnosis (circulatory vs. respiratory) did not define groups in
which ECMO treatment improved the microcirculation (8, 9).
Similarly, nor PELOD-2 score, IS or VIS defined a specific
group with an affected microcirculation that improved during
ECMO treatment. There are several possible explanations for
why the microcirculation was unaffected by ECMO treatment
in our study. Due to clinical instability and technical and
logistic issues, the microcirculation could only be assessed in
38% of patients before the initiation of ECMO. This possible
selection bias could have affected the results. However, the
patients who were not measured before ECMO treatment did not
differ from the patients who were measured based on PELOD-
2 score, type of ECMO, the primary indication for ECMO,
and overall mortality. Additionally, the microcirculation did not
differ at consecutive time points between these two groups. This
suggests that the possible selection bias does not explain the
lack of microcirculatory compromise and subsequent absence
of change in the microcirculatory parameters over time in our
study. Another explanation would be that ECMO treatment
may have been initiated before global systemic hemodynamics
deteriorated and influenced microcirculatory parameters. Also,
despite critical illness and altered global systemic hemodynamics,
which both affect microcirculatory function, themicrocirculation
has auto-regulatory mechanisms to preserve blood flow and
tissue oxygenation (17). These explanations are supported
by the relatively low lactate levels at the start of ECMO
treatment. Finally, our study population may have been too
small or heterogeneous to show effects or observe differences
over time. However, this is not the first study to find an
unaltered microcirculation during ECMO treatment. Similar to
our results, in neonates with severe respiratory failure treated
with VA ECMO, Top et al. reported that the PVD of the
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TABLE 5 | Repeated measures logistic regression (GEE) models for MFIall > 2.6 and MFI<20µm > 2.6.
Repeated measures logistic regression models: MFIall > 2.6 Odds ratio 95% CI p-value
Intercept (baseline odds) 0.652 0.018–23.460 0.815
Time point 0.336
Before start ECMO 0.188 0.017–2.127 0.188
After start ECMO/on day 1 0.045 0.003–0.663 0.045
ECMO day 2/3 0.036 0.002–0.667 0.036
ECMO day 4/5 0.021 0.000–1.327 0.021
ECMO day 6/7 0.064 0.003–1.199 0.064
After stop ECMO 1 (reference) – –
Pediatric patient (>28 days old) (c) 0.311 0.063–1.536 0.152
Duration ECMO (hrs) 1.009 1.002–1.015 0.009
MAP (mmHg) 1.068 0.989–1.153 0.093
PaO2 (kPa) 0.892 0.836–0.953 0.001
FiO2 of sweep gas flow ECMO (%) 1.026 0.997–1.057 0.077
Repeated measures logistic regression models: MFI
<20µm > 2.6 Odds ratio 95% CI p-value
Intercept (baseline odds) 1.843 0.025–135.438 0.780
Time point 0.149
Before start ECMO 0.047 0.004–0.583 0.017
After start ECMO/on day 1 0.449 0.097–2.070 0.304
ECMO day 2/3 0.204 0.026–1.612 0.132
ECMO day 4/5 0.354 0.033–3.831 0.392
ECMO day 6/7 0.692 0.065–7.424 0.761
After stop ECMO 1 (reference) – –
FiO2 (%) 1.022 0.996–1.048 0.101
Hemoglobin (mmol/L) 0.612 0.354–1.057 0.078
MAP (mmHg) 1.050 1.008–1.094 0.019
C, categorical variable; CI, confidence interval; FiO2, fraction inspired oxygen; MAP, mean arterial pressure; MFI, microcirculatory flow index; PaO2, partial oxygen pressure.
buccal microcirculation was unaltered after ECMO treatment
was started (10). In contrast to our findings, Top et al. also found
that after successful weaning from ECMO PVD was higher than
after starting ECMO treatment (18).
In contrast to our expectations, microcirculatory parameters
did not significantly differ between VV and VA ECMO. VV
ECMO is generally started for respiratory insufficiency. As
VA ECMO is started for cardiac failure or cardiorespiratory
failure, more effects on the microcirculation were expected both
before and after the initiation of VA ECMO. After starting
VV ECMO treatment, hypoxia was resolved quickly. Similarly,
hemodynamic instability was more often than not resolved
quickly after starting VA ECMO, apparent by declining need
of inotropic and vasoactive drugs. Then, for both types of
ECMO, global systemic hemodynamics are restored before
the microcirculation could deteriorate or the microcirculation
is preserved despite altered global systemic hemodynamics.
Another explanation could be that patients with pulmonary
hypertension [n = 5 (42% of VV ECMO patients)] treated with
VV ECMO are more comparable to VA ECMO patients than
one would expect. Patients with pulmonary hypertension can
present with hemodynamic instability, not different from patients
with cardiac failure. However, these patients with pulmonary
hypertension are treated with VV ECMO as this is often times
sufficient to resolve the pulmonary hypertension and indirectly
the hemodynamic instability that goes along with it (19, 20).
These VV ECMO patients and VA ECMO patients before
treatment might then have similar hemodynamics and similar
microcirculatory properties while being treated with different
ECMO entities.
PVD is used to assess the functional vessel density of
the microcirculation, a surrogate for the diffusive capacity,
i.e., the distance O2 covers from the RBC to the tissue cell
(12). Multivariable analyses showed that age group, sildenafil
treatment, and resuscitation with crystalloids had the biggest
impact on PVD. PVD was lower in pediatric patients than in
neonatal patients and in females than in males. This aligns
with findings from several observational studies performed in
healthy neonates and children, wherein these studies vessel
density of cutaneous and buccal microcirculation declined over
the first few weeks of life and vessel density of cutaneous
microcirculation was lower in females than in males (21–24).
Our comparable findings support the accuracy of the technique
used, because, despite these being highly complex and critically
ill children, the handheld vital microscopy yielded results in
which the effect of age and sex on the microcirculation could
still be distinguished from the other multiple factors affecting
the microcirculation. A possible explanation for age-related
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differences is the developmental changes of the cardiovascular
system, which have not yet been thoroughly investigated for
the microcirculation (25). PVD was also higher in (neonatal)
patients treated with sildenafil for pulmonary hypertension.
As sildenafil decreases vascular resistance through vasodilation,
blood flow through capillaries increases, which may account
for the increase of PVD. Similar effects were assessed with
handheld vital microscopy in an animal study on sildenafil
treatment and cardiorespiratory resuscitation by Wu et al. (26).
Although our data also suggest that norepinephrine decreases
PVD, this effect was only clinically relevant if high doses
(>1.0 µg/kg/min) were administered. This might explain why
Buijs et al. found that catecholaminergic drugs, including
norepinephrine, improved global systemic hemodynamics but
did not alter the microcirculation in neonates, as patients in
their study only received a median dose of 0.11 µg/kg/min
(IQR: 0.3) (27).
MFI is a qualitative measure of microvascular blood flow
velocity and describes the convective component of the
microcirculation (12). An MFI ≤ 2.6 is considered to be
disturbed flow, though this has not yet been validated in
children (3, 4). In our study, MAP and PaO2 levels had
the biggest influence on MFIall, while hemoglobin levels had
the biggest impact on MFI<20µm. MAP was also found to
influence the quality of flow and, thus, there seemed to be no
loss of hemodynamic coherence throughout ECMO treatment.
As systemic hemodynamics improved as MAP increased, this
increased the probability of having an MFI >2.6. Interestingly,
our study also found to have decreased probabilities for having
an MFI >2.6 with higher PaO2 levels, while having higher
probabilities with higher FiO2. One would expect a patient
with the need for higher FiO2 to have lower saturations and
lower PaO2 values, given that other hemodynamic parameters
are unaltered. However, it is not understood why a patient
who requires higher FiO2 and has lower PaO2 would be more
likely to have a better blood flow quality compared to a patient
who requires less FiO2 and has higher PaO2 levels. Finally,
increasing levels of hemoglobin increased the probability of
having an MFI >2.6. A similar finding was reported in an animal
study, in which after blood transfusions hemoglobin increased
concomitantly with increasing renal blood flow velocity (28).
In contrast, RBC transfusions in anemic preterm infants and
children improved both hemoglobin levels and PVD but did not
affect MFI values (29, 30).
While previous studies performed in adults demonstrated the
predictive value of microcirculatory parameters for outcome, our
study was not able to reach the same conclusion. The sublingual
microcirculation did not significantly differ between survivors
and non-survivors. Subsequently, sublingual microcirculatory
parameters before starting ECMO treatment, after starting
ECMO treatment, or on day 2 or 3 could not predict mortality
on ECMO or overall mortality. Although we expected that
the microcirculation in non-survivors would be compromised
before initiation of ECMO and would not improve, mortality
may not always be reflected in microcirculatory changes caused
by the underlying disease. In 24 adults with cardiogenic shock
treated with VA ECMO, Kara et al. showed that PVD differed
between survivors and non-survivors at all-time points (8).
Moreover, in this small group of patients, PVD after start ECMO
treatment could predict survival. In a similar population of 48
adults, Yeh et al. found differences in PVD and PPV between
survivors and non-survivors (31). The aforementioned studies
only included patients with cardiogenic shock, while our study
had a heterogeneous population with fewer cases of cardiogenic
shock. The MicroSOAP study, an international study with a
heterogeneous adult ICU study population with over 500 patients
showed that an abnormalMFI was independently associated with
increasedmortality risk if patients presented with tachycardia (3).
Similar observations could not be made in our study. Our study
may not have had sufficient power to test additional parameters
for their predictive value. However, to date there have been no
studies on the predictive value of microcirculatory parameters
in children, it is therefore uncertain if the microcirculation acts
differently in children than in adults. This could be especially
true in neonates, as they undergo developmental changes that
have not yet been fully investigated (21–23). Furthermore, in
our study, death was not always a result of cardiorespiratory
insufficiency but could also have resulted from irreversible
cerebral damage [n = 7 (47%)] or lack of further therapeutic
options [n = 3 (20%)], such as with refractory pulmonary
hypertension or severe heart failure without the option for heart
transplantation. These deceased patients did not necessarily have
a disturbed microcirculation, which is supported by the finding
that the medians and interquartile ranges of microcirculatory
parameters of our study population were higher than those of
the previously mentioned adult study populations (8, 31). It was
therefore unlikely that microcirculatory alterations could predict
outcome in this study population.
Whether microcirculatory parameters could also be used
in children as a biomarker for successful weaning from
ECMO treatment remains unclear. Microcirculatory parameters
measured before or after starting ECMO treatment, or on day
2 or 3 could not predict whether a patient could eventually be
successfully weaned from ECMO treatment. We were not able to
usemicrocirculatory parameters as a dynamic parameter to assess
whether patients could be successfully weaned, as Akin et al. did
in adults (9). Measurements could often not be performed during
the desired moment to attempt weaning, as patients were awake.
Also, while some institutions routinely perform trial offs to assess
whether patients can be weaned from ECMO, our institution
gradually decreases ECMO flow rate over time to eventually
clamp the ECMO circuit and wean patient from ECMO support.
Our study has some limitations that deserve mention.
Although handheld vital microscopy is non-invasive and
relatively easy to apply, practical issues account for the
missing values at different time points. The feasibility of
repeated microcirculatory measurements was limited, as our
study population comprised mostly of young patients. It is
challenging for young children, while being awake, to remain
motionless with their mouth and tongue for several seconds
during measurements, causing both movement and pressure
artifacts in the recorded imaging. This is especially the case for
neonates, as they exhibit a sucking reflex. Often times patients
were comfortably sedated but awake, did not cooperate or were
too unstable clinically to perform measurements with adequate
image quality. This led to the exclusion of 36% of the eligible
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patients and to missing data in the study population. These
challenges are not unique to our study. Gonzalez et al. showed
that in a general pediatric ICU population, microcirculatory
assessment was only possible in 17% of the patients (32). These
weremostly sedated and stable critically ill children. Additionally,
our study population comprised a heterogeneous group of
patients in terms of age, diagnosis, type, number, and severity of
organ failures and type of ECMO. However, the study population
was a representative sample of patients treated in our ECMO
program and in many ECMO units around the world (with the
exception of units that only use ECMO treatment in designated
cardiac patients). Yet, it is possible our study did not have enough
power to assess any change over time. Our sample size restricted
our multivariable analyses, as we could not correct for all factors
involved in these highly complex and critically ill patients.
Nevertheless, we were able to explore which covariates possibly
influenced the sublingual microcirculation. Future research is
necessary to confirm these findings. Another limitation is that
our observational study lacked a control group. However, it
would have been unethical to randomly allocate severely ill
patients to treatment with or without ECMO. Also, assessing
whether the microcirculation was disturbed or not was difficult,
since reference values for sublingual microcirculatory parameters
are lacking. Finally, it should be noted that the sublingual
microcirculation might not be reflective of microcirculatory
beds of vital organs and this could be one of the explanations
why sublingual microcirculatory parameters could not predict
outcome. Yet the sublingual microcirculation was and remains
an area of interest because of its easy accessibility for non-
invasive measurements and alterations in this microcirculatory
bed have been shown to be associated with increased morbidity
and mortality rates in several different settings including ECMO
patients (2, 33, 34).
To the best of our knowledge, this study is the first to
look at the sublingual microcirculation throughout neonatal
and pediatric ECMO treatment. Our study shows that the
microcirculation is not solely dependent on global systemic
hemodynamics and we have not yet elucidated this highly
integrated network of vessels and its role in oxygen transport
and tissue oxygenation. This study offers some insight in the
applicability and feasibility of handheld vital microscopy in
the neonatal and pediatric ECMO population. Our results
suggest that the focus of future research should shift from
routine monitoring of the microcirculation toward identifying
patient populations that could benefit from microcirculatory
monitoring, e.g., patients in cardiogenic shock. Evaluating the
microcirculation in patients in cardiogenic shock could offer
additional guidance for treatment strategies by showing whether
inotropic and vasoactive drug support and/or mechanical
support can sustain oxygen transport. More homogenous and
larger study populations are needed to properly assess the
effect of ECMO treatment on the microcirculation through
multicenter studies focusing on certain subpopulations who
receive ECMO treatment.
CONCLUSION
In our heterogeneous study population, we were not able to
demonstrate an effect of ECMO treatment on the sublingual
microcirculation. The microcirculation was unaltered
throughout ECMO treatment. Microcirculatory parameters
did not differ between VV and VA ECMO or between survivors
and non-survivors. Although monitoring of the microcirculation
with handheld vital microscopy offers additional information on
tissue oxygenation, its practice remains challenging in children.
Future research should focus on determining which neonatal and
pediatric ECMO patients would benefit from microcirculatory
monitoring and how.
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